SURMOUNT trial programme: difference between revisions
Diff·revision 1 → 2·18:28, 2 Aug 2024
Difference between revision 1 and revision 2 of SURMOUNT trial programme. 11 lines changed; the page grew by 943 bytes.
| Revision 1 — 07:08, 2 Aug 2024 DrTitration (talk) new article: trial programme, expansion welcome 1,114 bytes +1,114 | Revision 2 — 18:28, 2 Aug 2024 DataTableDunja (talk) add the confidence interval to the point estimate 2,057 bytes +943 | ||
|---|---|---|---|
| 10 | Mean weight change was −15.0%, −19.5% and −20.9% at the three doses against −3.1% on placebo. Both arms received lifestyle counselling, so the placebo figure is not a no-treatment baseline; see [[Placebo-adjusted effect]].{{r|jastreboff2022}} | 10 | Mean weight change was −15.0%, −19.5% and −20.9% at the three doses against −3.1% on placebo. Both arms received lifestyle counselling, so the placebo figure is not a no-treatment baseline; see [[Placebo-adjusted effect]].{{r|jastreboff2022}} |
| 11 | 11 | ||
| + | 12 | == Constituent trials == | |
| + | 13 | | Trial | Population | Duration | Result at highest dose | | |
| + | 14 | |---|---|---|---| | |
| + | 15 | | SURMOUNT-1 | Obesity, no diabetes | 72 weeks | −20.9% vs −3.1% | | |
| + | 16 | | SURMOUNT-2 | Obesity with type 2 diabetes | 72 weeks | −14.7% vs −3.2% | | |
| + | 17 | | SURMOUNT-3 | After intensive lifestyle lead-in | 72 weeks | Further loss after lead-in | | |
| + | 18 | | SURMOUNT-4 | Randomised withdrawal after lead-in | 88 weeks total | Regain on withdrawal | | |
| + | 19 | ||
| + | 20 | SURMOUNT-4 is the counterpart of STEP 4 and addresses the same question: what happens when treatment stops. Participants randomised to placebo after a lead-in regained a substantial proportion of the weight lost. See [[Weight regain after discontinuation]].{{r|garvey2023}} | |
| + | 21 | ||
| 12 | == References == | 22 | == References == |
| 13 | {{reflist}} | 23 | {{reflist}} |
| 14 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> | 24 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> |
| + | 25 | <ref name="garvey2023">Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." ''The Lancet'' 402(10402):613–626 (2023). PMID 37385275.</ref> | |
| 15 | 26 | ||
| 16 | {{DEFAULTSORT:SURMOUNT trial programme}} | 27 | {{DEFAULTSORT:SURMOUNT trial programme}} |